Skip to content

    Sai Life

    SAILIFEStrong
    Healthcare·8 Aug 2025
    Management Summary

    Sai Life Sciences delivered an exceptionally strong start to FY26, characterized by triple-digit growth in its CDMO segment and a significant turnaround in bottom-line profitability. Management is aggressively investing in capacity, with a ₹700 crore capex plan for the current year to double Process R&D and expand manufacturing by 80% by 2027. The company is successfully pivoting toward high-growth modalities like ADCs and oligonucleotides while benefiting from 'China Plus One' diversification trends.

    Highlights

    8
    • Revenue reached ₹496 crores, a 77% YoY increase driven by strong CDMO performance

    • EBITDA surged 305% YoY to ₹125 crores, with margins expanding 1,400 bps to 25%

    • CDMO business grew 113% YoY to ₹314 crores; CRO business grew 38% to ₹182 crores

    • Turnaround in profitability with PAT of ₹60 crores vs a loss of ₹13 crores in Q1 FY25

    • Aggressive Capex plan of ₹700 crores for FY26 to support capacity expansion

    • Manufacturing capacity targeted to increase by 80% by 2027 (adding ~450-550 KL)

    • Process R&D capacity expected to double by next year

    • Onboarded 250+ scientists and technical professionals during the quarter

    What Changed2

    vs Q2 FY26

    Tone shiftGood → StrongGuidance items4 → 5 (+1)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹496 Cr+77%YoY
    2. 02EBITDA₹125 Cr+3.0%YoY
    3. 03EBITDA Margin25%
    4. 04PAT₹60 Cr
    5. 05Capex₹134 Cr

    Segment breakdown

    • CDMO₹314 Cr63.3%
    • CRO₹182 Cr36.7%
    Donut· Share of Revenue

    Guidance & targets

    5
    CategoryTargetPriority
    Revenue
    Average Growth Rate
    15%
    High
    Margin
    EBITDA Margin
    28%-30%
    Medium
    Capex
    Annual Capex
    ₹700 crores
    High
    Capacity
    Manufacturing Capacity Increase
    80%
    High
    Capacity
    Process R&D Capacity
    Double
    High

    Risks & concerns

    5
    RiskSeverity

    CDMO Revenue Lumpiness

    Management reiterated that the CDMO business is inherently lumpy and should be reviewed on a long-term rather than quarterly basis.Management acknowledged

    medium

    Clinical Trial Failures

    The Phase III pipeline saw a reduction from 10 to 6 molecules, with management confirming some were due to clinical trial failures.Both acknowledged

    medium

    Geopolitical and Reshoring Pressures

    Management believes US reshoring will focus on final formulations/fill-finish, while R&D and intermediate manufacturing will remain in Asia.Analyst downplayed

    low

    Areas of Evasion(2)

    • Specific molecule details in the Phase III pipeline
    • Total scientist headcount across segments (promised to send separately)

    Q&A highlights

    3

    “that's a general trend that we have seen across the years and we believe that trend will continue, but I am not giving any specific guidance for this year.”

    Confirms that the strong Q1 is not a one-off and the historical trend of a stronger second half remains intact.

    asked by Binay, Morgan Stanley

    2 min read5 chapters

    Detailed Narrative

    01

    Explosive Growth and Margin Expansion

    Sai Life reported a 77% YoY revenue jump to ₹496 crores, underpinned by a 113% surge in the CDMO segment. This scale led to significant operating leverage, with EBITDA margins expanding from 11% to 25% YoY. Management is confident that as revenues continue to scale, they can reach a steady-state EBITDA margin of 28-30%.

    02

    Aggressive Capacity Roadmap

    The company is in the midst of a massive expansion phase, targeting an 80% increase in manufacturing capacity by 2027. This includes adding two new production blocks by the second half of next year. Furthermore, Process R&D capacity is set to double by next year, and Discovery space will increase by 30% by the end of FY26 to support complex integrated programs.

    03

    Strategic Pivot to New Modalities

    Sai Life is moving beyond traditional small molecules into high-value modalities including ADCs, oligonucleotides, peptides, and lipids. Management noted they are already working on late-phase commercial assets for ADCs and are 'fairly far ahead' in oligonucleotides. These modalities are expected to be key drivers of future revenue and margin profile.

    04

    China Plus One and IP Security

    Geopolitical shifts are providing a tailwind as global pharma innovators seek to diversify supply chains away from China. Management highlighted that IP concerns in China, where local firms are becoming competitors in discovery, are driving customers toward Indian partnerships. They believe this is a long-term structural shift that will take years to fully play out.

    05

    Pipeline Dynamics and Clinical Risks

    While the overall business is growing, the late-stage pipeline saw some volatility, with the number of Phase III/pre-registration molecules dropping to 6 from a previous 10. This was a net result of two molecules moving to commercial stage and others being dropped due to clinical trial failures. Management emphasized that such failures are an inherent risk in the CDMO model and outside their direct control.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.